Summary
57 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: £15.9M against £1.46M.
- Out of every 100 GBP of revenue, 12 GBP is left as free cash.
What to watch
- Revenue fell by 8.2% a year over the last 3 years.
- The share price is above the Bulios Fair Price.
- It earns only 3.8 GBP a year on every 100 GBP of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 41.7 GBP for 1 GBP of yearly profit. Over the last five years it was 36.5 GBP on average.
Valuation in detailIs it growing?
SlowlyRevenue (GBP)
Diluted EPS (GBP)
- Analyst estimate
Revenue fell by 4.6% a year over 5 years. Over the last 3 years it fell by 8.2% a year.
Growth in detailDoes it make money?
ReasonablyWhere 100 GBP of revenue goes
- Cost of sales 47 GBP
- Research and development 2.3 GBP
- Sales and administration 37 GBP
- Taxes and other 8.4 GBP
- Net profit 4.9 GBP
Net profit, industry median (Medical - Devices) 6.5 GBP
Out of every 100 GBP of revenue, 4.9 GBP is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.